Clinical trial
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
NCT00310375 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00310375 |
|---|---|
| Title | Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial |
| Official title | A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301) |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Epilepsy |
| Intervention type | Drug |
| Interventions | Ezogabine: USAN Retigabine (International Nonproprietary Name) |
| Enrollment | 181 |
| Start date | May 1, 2006 |
| Primary completion | Nov 30, 2016 |
| Completion | Mar 15, 2017 |
| First posted | Apr 3, 2006 |
| Last update posted | Jul 31, 2020 |
| Countries | Argentina, Brazil, Canada, Mexico, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: